Lucid Diagnostics Inc.
LUCD
Rank in Stocks
#20715
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on... Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
Share Price
$0.4175
Last synced: 2026-11-09
Market Cap
$79.72M
Change (1 day)
4.90%
Change (1 year)
-59.86%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Lucid Diagnostics Inc. (LUCD)
Category
Healthcare
Operating Margin for Lucid Diagnostics Inc. (LUCD)
Operating Margin as of November 2026 TTM: -930.85%
According to Lucid Diagnostics Inc.'s latest financial reports, its current operating margin (TTM) is -930.85%. At the end of 2025 the company had an operating margin of -1,054.82%.
Operating Margin history for Lucid Diagnostics Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -930.85% | -11.75% |
| 2025 | -1,054.82% | -0.45% |
| 2024 | -1,059.64% | -46.93% |
| 2023 | -1,996.79% | -86.60% |
| 2022 | -14,899.47% | 171.70% |
| 2021 | -5,483.80% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -100.02% |
US
|
|
| 18.08% | -100.02% |
IE
|
|
| 21.25% | -100.02% |
US
|
|
| 21.05% | -100.02% |
US
|
|
| 28.09% | -100.03% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Lucid Diagnostics Inc.'s operating margin
What is Lucid Diagnostics Inc.'s operating margin?
Lucid Diagnostics Inc.'s operating margin is -930.85%, as of Nov 2026.
What was Lucid Diagnostics Inc.'s operating margin in 2025?
In 2025, Lucid Diagnostics Inc.'s operating margin was -1,054.82%, compared with -1,059.64% in 2024.
How has Lucid Diagnostics Inc.'s operating margin changed since 2020?
From 2020 to 2025, Lucid Diagnostics Inc.'s operating margin was highest in 2020 (0.00%) and lowest in 2022 (-14,899.47%).
How does Lucid Diagnostics Inc.'s operating margin compare with similar companies?
Lucid Diagnostics Inc.'s operating margin (-930.85%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.